Outsourced Pharma Capacity Update Videos - Small Molecule

  1. Upperton Pharma Solutions Capabilities Update April 2026: Small Molecule Drug Product 4/28/2026

    Learn more about UK-CDMO, Upperton Pharma Solutions, and their expertise across oral, nasal, pulmonary and sterile drug product development and manufacturing

  2. Thermo Fisher Scientific Capabilities Update April 2026: Small Molecule Drug Product 4/28/2026

    Align formulation, process, and scale strategy early to support larger batches, new equipment, and commercial manufacturing — cutting rework and speeding Phase I to launch.

  3. Douglas CDMO Capabilities Update April 2026: Small Molecule Drug Product 4/28/2026

    Douglas CDMO assists pharmaceutical and biotechnology companies with their contract manufacturing and development needs, specializing in high-potency softgels and liquids.

  4. Bora Pharmaceuticals Capabilities Update April 2026: Small Molecule Drug Product 4/28/2026

    Bora Pharmaceuticals is a global CDMO specializing in small molecule drug product development and manufacturing from clinical through commercial supply.

  5. Adare Pharma Solutions Capabilities Update April 2026: Small Molecule Drug Product 4/28/2026

    With a proven history in drug delivery, Adare’s facilities in the US and Europe have developed and manufactured more than 65 products sold by customers worldwide.

  6. Quotient Sciences Capabilities Update March 2026: Small Molecule Drug Product 3/11/2026

    This session is designed to help you assess which development approaches, locations, and timelines may be most appropriate for your asset.

  7. Pfizer CentreOne Capabilities Update March 2026: Small Molecule Drug Product 3/11/2026

    From development through commercial supply, our integrated capabilities and rigorous quality standards ensure reliable execution and consistent performance at every stage.

  8. PCI Pharma Services Capabilities Update March 2026: Small Molecule Drug Product 3/11/2026

    Gain insight into our SMART FHD™ approach, designed to accelerate early-phase development through streamlined first-human-dose readiness, as well as its integrated partner network for targeted protein degraders (TPDs).

  9. Mikart Capabilities Update March 2026: Small Molecule Drug Product 3/11/2026

    Discover how integrated formulation development, scalable manufacturing, and robust facility infrastructure can streamline your small molecule programs from early development through commercial production with confidence.

  10. Asymchem Capabilities Update March 2026: Small Molecule Drug Product 3/11/2026

    Guided by a technology-driven approach and supported by a highly coordinated development and manufacturing ecosystem, we provide high-quality, efficient drug product solutions aligned with stringent global regulatory standards.